Abstract:

ObjectiveTo evaluate the effect and safety of decitabine （DAC） combined HIA regimen （homoharringtonine， idarubicin and cytarabine） and FLAG regimen（fludarabine, cytarabine and granulocyte colonystimulating factor） on relapsed or refractory acute myeloid leukemia （AML）. Methods Fifty patients with relapsed or refractory AML who received chemotherapy were retrospectively analyzed， including 17 patients receiving DAC+HIA regimen as observation group and 33 patients receiving FLAG regimen as control group. The complete remission rate， overall response rates （RR）， overall survival （OS）， relapse free survival （RFS） and adverse reactions rate were observed and analyzed. Kaplan-Meier method was used to estimate survival. Results The complete remission rate of observation group was higher than that of control group （64.7％ vs. 33.3％， P＜0.05）. Median OS and median RFS of observation group did not reach，while median OS and median RFS of control group were 654 d and 612 d. The mortality rates of both groups were 35.3％ and 42.4％，and relapse rates were 18.2％ and 45.5％. Infections with different degrees were the main adverse reaction in both groups （70.6％ vs. 87.8％）. Conclusion Decitabine combined HIA regimen is suitable for relapsed or refractory AML patients which is associated with a higher complete remission rate， and it is safe and reliable.